By PPN News Staff
The FDA granted approval for nivolumab (Opdivo, Bristol-Myers Squibb) to treat patients with hepatocellular carcinoma who have received previous treatment with sorafenib (Nexavar, Bayer).
The burden of hepatocellular carcinoma (HCC) in the United States is significant and is expected to increase in the coming decades. A recently released report from the American Cancer Society (ACS) noted that death rates from liver cancer are increasing at a faster pace than any other cancer,